Annual report pursuant to Section 13 and 15(d)

SHARE CAPITAL (Tables)

v3.7.0.1
SHARE CAPITAL (Tables)
12 Months Ended
Mar. 31, 2017
Stockholders' Equity Note [Abstract]  
Schedule of Stockholders Equity [Table Text Block]
 
 
March 31, 2017
 
March 31, 2016
 
 
 
Number of shares
 
$
 
Number of shares
 
$
 
Exchangeable Shares:
 
 
 
 
 
 
 
 
 
Balance beginning of period
 
 
50,000,000
 
 
50,000
 
 
50,000,000
 
 
50,000
 
Converted into common shares
 
 
(2,090,664)
 
 
(2,090)
 
 
-
 
 
-
 
Balance at end of period
 
 
47,909,336
 
 
47,910
 
 
50,000,000
 
 
50,000
 
Common Shares
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at beginning of the period
 
 
22,591,292
 
 
22,591
 
 
22,428,313
 
 
22,428
 
Shares issued on acquisition (Note 3)
 
 
23,650,000
 
 
23,650
 
 
-
 
 
-
 
Shares issued to exchangeable shareholders
 
 
2,090,664
 
 
2,090
 
 
-
 
 
-
 
Shares issued for services (f)
 
 
217,047
 
 
217
 
 
117,471
 
 
117
 
Options exercised
 
 
110,096
 
 
110
 
 
-
 
 
-
 
Warrants exercised
 
 
174,759
 
 
175
 
 
-
 
 
-
 
Cashless exercise of warrants (iv)
 
 
51,249
 
 
51
 
 
45,508
 
 
46
 
Balance at end of the period
 
 
48,885,107
 
 
48,884
 
 
22,591,292
 
 
22,591
 
TOTAL COMMON SHARES
 
 
96,794,443
 
 
96,794
 
 
72,591,292
 
 
72,591
 
 
(a)
On April 21, 2015, the Company issued 3,115,000 Units for gross proceeds of $2,492,000 to accredited investors in a fourth closing (the “Fourth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other related to the Fourth Closing of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 11). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $435,682 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
 
(b)
On May 27, 2015, the Company issued 1,418,750 Units for gross proceeds of $1,135,000 to accredited investors in a fifth closing (the “Fifth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Fifth Closing of $147,566 and issued 141,875 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 11). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $37,739 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
 
(c)
On June 30, 2015, the Company issued 2,035,000 Units for gross proceeds of $1,628,000 to accredited investors in a sixth and final closing (the “Sixth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Sixth Closing of $211,656 and issued 203,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 11). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $74,625 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
 
(d)
During the year ended March 31, 2016, 53,223 shares of common stock related to services were issued. During the year ended March 31, 2016, 134,248 shares of common stock were issued related to investor relations and consulting services provided in 2016 valued at $75,600.
 
(e)
During the year ended March 31, 2016, 45,508 shares of common stock were issued as a result of a cashless exercise of 148,787 warrants with an exercise price of $0.80 under the terms of the warrant agreement. The value of the warrants on exercise was attributed to the shares on exercise. As a result, $60,966 was reclassified from warrant derivative liability to additional paid in capital.
 
(f)
During the year ended March 31, 2017, the Company issued 70,000 shares of common stock with a value of $59,500, 60,000 shares of common stock with a value of $36,000 and 87,047 shares of common stock with a value of $62,288 for services provided.
 
(g)
During the year ended March 31, 2017, the Company issued, 51,249 shares of common stock were issued as a result of a cashless exercise of 262,045 warrants with an exercise price of $0.80.
 
(h)
On April 21, 2016, the Company acquired 100% of the capital stock of IMT through a transaction where Bionik issued 23,650,000 shares of common stock.
 
(i)
During the year ended March 31, 2017, 174,759 warrants were exercised for proceeds of $40,195 and 110,096 options were exercised for proceeds of $18,166.
 
(j)
During the ended March 31, 2017, holders of 2,090,664 exchangeable shares elected to convert their shares into shares of common stock of the Company.